(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 12.81% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.92%.
Cytosorbents's revenue in 2026 is $37,200,000.On average, 4 Wall Street analysts forecast CTSO's revenue for 2026 to be $2,450,753,425, with the lowest CTSO revenue forecast at $2,286,733,543, and the highest CTSO revenue forecast at $2,595,620,909. On average, 3 Wall Street analysts forecast CTSO's revenue for 2027 to be $3,018,229,563, with the lowest CTSO revenue forecast at $2,899,924,257, and the highest CTSO revenue forecast at $3,107,021,336.
In 2028, CTSO is forecast to generate $3,304,699,203 in revenue, with the lowest revenue forecast at $3,175,090,843 and the highest revenue forecast at $3,401,905,473.